Recent

% | $
Quotes you view appear here for quick access.

Dendreon Anonim Ortaklik Message Board

  • greatdayforinvestments greatdayforinvestments Feb 26, 2014 2:32 PM Flag

    Northwest's (NWBO) DCVax-Prostate survival 38.7 months vs. Provenge survival 25.9 months

     

    DCVax®- Prostate
    Completed multi-center Phase I / II trial with 36 patients

    Showed positive efficacy signal and good safety (no toxicity)

    Hormone Independent Non-Metastatic Prostate Cancer:
    Median survival Standard of Care 36 months.
    Median Survival DCVax-Prostate 54 months ( half were still alive )

    Hormone Independent Metastatic Prostate Cancer
    Median survival Standard of Care 18.9 months (Taxotere)
    Dendreon's Provenge 25.9 months
    Median Survival DCVax-Prostate 38.7 months

    Hormone Independent Metastatic Prostate Cancer - Overall Survival at 3 years
    Median survival Standard of Care 11%
    Dendreon's Provenge 33%
    Median Survival DCVax-Prostate 64%

    FDA has approved 612-patient Phase III prostate cancer trial design
    Company is seeking to out-license this program

    Sentiment: Strong Buy

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
DNDN
0.00(0.00%)